Those who have received the Moderna Covid-19 mRNA vaccine are less likely to experience "breakthrough" Covid-19 cases, compared to recipients of the Pfizer-BioNTech mRNA vaccine, finds a new study.
The research, published in the Journal of the American Medical Association, also found those who received the Moderna vaccine were less likely to be hospitalised, compared to recipients of the Pfizer-BioNTech vaccine.
"Breakthrough Covid infections, hospitalisation and mortality associated with the Delta variant were compared between recipients of Moderna mRNA vaccine and recipients of Pfizer mRNA vaccine while considering patient characteristics and the varying time since vaccination," said researcher Rong Xu from Case Western Reserve University.
A vaccine breakthrough infection occurs when a person becomes infected after being fully vaccinated (receiving two doses of the mRNA vaccine), according to the Centers for Disease Control and Prevention in the US.
For the study, which examined breakthrough SARS-CoV-2 infections, hospitalisations and death rates when the Delta variant was predominant, the team analysed electronic health records of more than 637,000 fully vaccinated patients.
Incidents of breakthrough infections were included if the person had not been previously infected with Covid-19 or had received a booster vaccination.
The findings showed that the monthly incidence rate of breakthrough cases was higher in those who received the Pfizer BioNTech vaccine, compared to the Moderna vaccine.
No significant difference was observed in mortality rates between those who received the Moderna vaccine and Pfizer- BioNTech vaccine.
--IANS
vc/svn/bg
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU